↓ Skip to main content

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Overview of attention for article published in Diagnostic Pathology, July 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
6 X users
facebook
1 Facebook page
reddit
1 Redditor

Citations

dimensions_citation
70 Dimensions

Readers on

mendeley
55 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
Published in
Diagnostic Pathology, July 2015
DOI 10.1186/s13000-015-0362-5
Pubmed ID
Authors

I. Watermann, B. Schmitt, F. Stellmacher, J. Müller, R. Gaber, Ch. Kugler, N. Reinmuth, R. M. Huber, M. Thomas, P. Zabel, K. F. Rabe, D. Jonigk, A. Warth, E. Vollmer, M. Reck, T. Goldmann

Abstract

Several c-MET targeting inhibitory molecules have already shown promising results in the treatment of patients with Non-small Cell Lung Cancer (NSCLC). Combination of EGFR- and c-MET-specific molecules may overcome EGFR tyrosine kinase inhibitor (TKI) resistance. The aim of this study was to allow for the identification of patients who might benefit from TKI treatments targeting MET and to narrow in on the diagnostic assessment of MET. 222 tumor tissues of patients with NSCLC were analyzed concerning c-MET expression and activation in terms of phosphorylation (Y1234/1235 and Y1349) using a microarray format employing immunohistochemistry (IHC). Furthermore, protein expression and MET activation was correlated with the amplification status by Fluorescence in Situ Hybridization (FISH). Correlation was observed between phosphorylation of c-MET at Y1234/1235 and Y1349 (spearman correlation coefficient rs = 0.41; p < 0.0001). No significant correlation was shown between MET expression and phosphorylation (p > 0.05). c-MET gene amplification was detected in eight of 214 patients (3.7 %). No significant association was observed between c-MET amplification, c-MET protein expression and phosphorylation. Our data indicate, that neither expression of c-MET nor the gene amplification status might be the best way to select patients for MET targeting therapies, since no correlation with the activation status of MET was observed. We propose to take into account analyzing the phosphorylation status of MET by IHC to select patients for MET targeting therapies. Signaling of the receptor and the activation of downstream molecules might be more crucial for the benefit of therapeutics targeting MET receptor tyrosine kinases than expression levels alone.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 55 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 20%
Student > Master 9 16%
Student > Ph. D. Student 8 15%
Other 6 11%
Student > Bachelor 5 9%
Other 6 11%
Unknown 10 18%
Readers by discipline Count As %
Medicine and Dentistry 20 36%
Biochemistry, Genetics and Molecular Biology 10 18%
Agricultural and Biological Sciences 6 11%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Psychology 1 2%
Other 3 5%
Unknown 13 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 August 2015.
All research outputs
#5,652,339
of 22,818,766 outputs
Outputs from Diagnostic Pathology
#127
of 1,127 outputs
Outputs of similar age
#64,862
of 263,394 outputs
Outputs of similar age from Diagnostic Pathology
#12
of 77 outputs
Altmetric has tracked 22,818,766 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,127 research outputs from this source. They receive a mean Attention Score of 2.8. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,394 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.